Interim report January - June 2001

Report this content

INTERIM REPORT JANUARY - JUNE 2001 * Continued substantial increase in turnover of 62 percent up to SEK 174.0 (107.5) million. For a rolling 12 months turnover increased by 72 percent to SEK 303.7 (176.2) million. * Operating income for comparable units (excluding Ixion) was SEK 30.5 (17.8) million, corresponding to an operating margin of 17.5 (16.6) percent. Ixion's effect on the operating income was SEK -14.3 (-) million. * DUROLANE approved for sales in Europe. * Strong increase in profits (79%) within Esthetics 58.9 (32.9) million - operating margin amounted to 35 percent. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/08/22/20010822BIT00700/bit0001.doc Full Report http://www.waymaker.net/bitonline/2001/08/22/20010822BIT00700/bit0002.pdf Full Report

Documents & Links